Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
General Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
How does triple-negative status influence your management of ET?
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
How do you approach management for CCUS with severe cytopenias?